CIA
NBIX icon

Caerus Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Caerus Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$333K Sell
2,526
-2,726
-52% -$362K 0.14% 154
2025
Q4 		$745K Buy
5,252
+519
+11% +$75.2K 0.24% 86
2025
Q3 		$664K Buy
+4,733
New +$641K 0.27% 75

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caerus Investment Advisors's NBIX Position: Q1 2026 in Review

Caerus Investment Advisors reduced its Neurocrine Biosciences (NBIX) stake by 52% in Q1 2026, selling an estimated $362K and leaving 2,526 shares worth $333K. The position accounts for 0.14% of the portfolio, ranked #154.

Caerus Investment Advisors first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $745K in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Caerus Investment Advisors held 2,526 shares of Neurocrine Biosciences worth $333K as of Q1 2026.
  • Caerus Investment Advisors sold 2,726 Neurocrine Biosciences shares in Q1 2026, an estimated $362K.
  • Neurocrine Biosciences made up 0.14% of Caerus Investment Advisors's portfolio in Q1 2026, its #154 holding.
  • Caerus Investment Advisors first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Caerus Investment Advisors's Neurocrine Biosciences position peaked at $745K in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Caerus Investment Advisors's 13F filing for Q1 2026, filed 1 Jun 2026.